Results for hypertrophic translation from English to Maltese

rare cases of hypertrophic granulation have been reported.
Ġew irrapurtati każijiet rari ta ’ granulazzjoni ipertrofika.

aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy
stenosi tal-valv mitrali u aortiku, kardjomijopatija ipertropika ostruttiva

patients may require debridement of the hypertrophic tissue via arthroscopy.
il-pazjenti jistgħu jkunu jeħtieġu tneħħija tat-tessut ipertrofiku mhux f’saħħtu jew mejjet permezz ta’ artroskopija.

31 aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
pazjenti b’ aldosteroniżmu primarju ġeneralment mhux ser jirrispondu għal prodotti mediċinali kontra l- pressjoni għolja li jaġixxu permezz ta ’ l- inibizzjoni tas- sistema renin - angiotensin.

both the events of hypertrophic scarring were medically confirmed; in one case the scar was persistent after 12 months.
iż-żewġ avvenimenti ta' ċikatriċi ipertrofika ġew ikkonfermati medikament; f'każ wieħed, iċ-ċikatriċi kienet persistenti wara 12-il xahar.

as with all other vasodilators, special caution is indicated in patients with aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
bħalma jiġri bis-sustanzi vażodilataturi l-oħrajn kollha, kawtela speċjali hi indikata f’pazjenti bi stenożi tal-aorta jew tal-mitrija, jew kardjomijopatija ipertrofika ostruttiva.

as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
bħal fil-każ ta’ mediċini oħrajn li jwessgħu l-arterji/vini, għandha tingħata attenzjoni speċjali lil pazjenti li jbatu minn stenosi mitrali jew aortika, jew kardjomijopatija ipertropika ostruttiva.

as with all other vasodilators, special caution is indicated when using amlodipine in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
bħalma jseħħ b’vażodilataturi oħrajn, hija indikata kawtela speċjali meta jintuża amlodipine f’pazjenti li jbatu minn stenożi tal-aorta jew mitrali, jew b’kardjomijopatija ipertrofika ostruttiva.

obstruction of the outflow tract of the left ventricle (e.g. hypertrophic obstructive cardiomyopathy and high grade aortic stenosis).
imblokk tal-passaġġ ta’ tfigħ ’il barra tal-ventrikolu tax-xellug (eż. kardjomijopatija ipertrofika ostruttiva u stenosi aortika ta’ grad għoli).

the thickness of the heart muscle (hypertrophic cardiomyopathy) or cardiogenic shock (not enough blood supply to your tissues)
fil- muskolu tal- qalb (kardjomijopatija ipertrofika) jew xokk kardjoġeniku (m’ hemmx biżżejjed forniment ta ’ demm fit- tessuti tiegħek),

patients with left ventricular outflow obstruction, e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis, can be sensitive to the action of vasodilators including type 5 phosphodiesterase inhibitors.
pazjenti li ġħandhom imblukkar tal-ħruġ mill-ventrikulu tax-xellug, eż., stenożi ta’ l-aorta, stenożi subaortika ipertrofika idjopatika, jistgħu jkunu sensittivi għall-azzjoni ta’ vażodilataturi inklużi impedituri ta’ phosphodiesterase tat-tip 5.

furthermore, brinavess has not been evaluated in patients with clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis and its use cannot be recommended in such cases.
barra minn hekk, brinavess ma ġiex evalwat f’pazjenti li kellhom stenożi valvolari klinikament sinifikanti, kardjomijopatija ipertrofika ostruttiva, kardjomijopatija restrittiva, jew perikardite kostrittiva u l-użu tiegħu ma jistax jiġi rrakkomandat f’każijiet bħal dawn.

aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
stenożi tal-valv aortiku u mitrali, kardjomijopatija ipertrofika ostruttiva: bħal fil-każ ta’ vażodilatorji oħra, għandha tingħata attenzjoni speċjali f’pazjenti li jsofru minn stenożi aortika jew mitrali jew kardjomijopatija ipertrofika ostruttiva.

do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic or pulmonary stenosis).
tużax f’każijiet ta’ kardjomijopatiji ipertrofiċi jew kundizzjonijiet kliniċi fejn żieda fil-produzzjoni tal- qalb ma tkunx possibbli għal raġunijiet funzjonali jew anatomiċi (eż. stenożi tal-aorta jew pulmonari).

alert hcp about brinavess special warnings and precautions in patients with, clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis, previously documented lvef ≤ 35%, advanced hepatic impairment.
wissi lill-hcp dwar twissijiet u prekawżjonijiet speċjali ta’ brinavess f’pazjenti bi stenożi valvulari klinikament importanti, kardjomijopatija ostruttiva ipertrofika, kardjomijopatija restrittiva, jew perikardite kostrittiva, lvef iddokumentata preċedentament ≤ 35%, indeboliment avvanzat tal-fwied.